CD163 and neoplasm: Using the Lunaphore COMETTM spatial multiplex platform, we further evaluated the immune spatial landscape in 2 GBM patients by staining for B cells (CD20+), T cells (CD8+), myeloid cells (CD163+), epithelial cells (CD31+), tumor cells and astrocytes (GFAP+).